Answers are grounded in this paper and cite their sources.
Standardized MSC-EV production strategies may not be sufficient to warrant manufacturing of MSC-EV products with reproducible qualities. Consequently, given this functional heterogeneity, every individual MSC-EV preparation considered for the clinical application should be evaluated for its therapeutic potency before administration to patients. Here, upon comparing immunomodulating capabilities of independent MSC-EV preparations in vivo and in vitro, we found that the mdMLR assay was qualified for such analyses.
No takes yet. Share an insight, caveat, or question.
Madel et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: